Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
This study is currently recruiting participants.
Verified April 2013
by M.D. Anderson Cancer Center
Study NCT01518153 Information provided by M.D. Anderson Cancer Center
First Received on January 23, 2012. Last Updated on April 30, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Lymphoma
Myeloma
Myeloproliferative Diseases
Additional conditions recognized in this trial
Multiple Myeloma
Myeloproliferative Disorders
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Bone Marrow Diseases
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Fludarabine
Melphalan
Alemtuzumab
Stem Cell Infusion
Tacrolimus
Methotrexate
G-CSF
Low Dose Donor T-Cells
High Dose Donor T-Cells
Additional drug interventions recognized in this trial
Campath 1G
Fludarabine monophosphate
Lenograstim
Vidarabine
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Adjuvants, Immunologic
Alkylating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Antiviral Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Back to top of Main Content
